LIVANOVA PLC (LIVN)
Health Care · Medical Devices · NASDAQ
LivaNova is a medical device company specializing in advanced therapies for cardiac surgery and neurological disorders, including epilepsy and sleep apnea.
What LIVANOVA PLC does
LivaNova PLC is a medical technology company focused on cardiovascular and neuromodulation solutions. The company develops and markets devices for cardiac surgery, such as cardiopulmonary bypass systems, as well as neuromodulation therapies for the treatment of drug-resistant epilepsy and obstructive sleep apnea.
Themes: cardiovascular surgery, neuromodulation, epilepsy treatment, sleep apnea therapy
Fundamentals
- Price$78.26 as of 2026-08-24 close
- Market cap$4.3B as of 2026-08-24
- 1-year return+40.0% 2025-08-22 close $55.90 → 2026-08-24 close $78.26
- P/E23.16 as of 2026-08-24
- Net margin+12.8% as of 2026-08-24
- Gross margin+68.1% as of 2026-08-24
- ROE+15.4% as of 2026-08-24
- Debt / equity0.22 as of 2026-08-24
- Revenue growth (YoY)+12.4% as of 2026-08-24
- Revenue CAGR (3y)+10.8% SEC XBRL
- Beta0.94 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How LIVN compares in its sector
- price-to-earnings ratiomiddle range 191 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
LIVN is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
43.4 #1217 of 1,704 scored · #197 of 240 in Health Care
Trend 50th: a "golden cross" — its 50-day average is above its 200-day; momentum 49th: mid-range on the stochastic oscillator; weakest is volume and participation 18th: it gapped 6.4% below the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How LIVANOVA PLC looks technically
LIVANOVA PLC (LIVN) is trading 15.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 256 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day low about 12 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 15.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +15.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $80.49 | $80.49 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $68.16 | $68.16 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 82.7. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 256 trading days ago — a "golden cross", a bullish long-term signal | 256 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 12.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($74.67 to $85.76) — its "stochastic" reading is 37 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 36.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $85.76 | $85.76 |
|---|---|---|
| From the 52-week high | it is 8.2% below its 52-week high (its highest price of the past year) | -8.2% |
| Above the 52-week low | it is 61.3% above its 52-week low (its lowest price of the past year) | +61.3% |
| Below the 52-week high | it is 8.2% below its highest point of the past year | 8.2% |
| Since a 20-day breakout | it made a new 20-day low about 12 trading days ago | 12 sessions |
| Since a 55-day breakout | it made a new 55-day high about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $131.54 (set on 2018-09-12) | $131.54 |
| Given back of the 52-week move | over the past year its closes ranged ($49.57 to $85.33), and it has given back roughly a quarter of its rise from last year’s low — 18% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $62.08 to $63.23. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 18.4% |
| From the all-time high | it is 40.1% below its all-time high | -40.1% |
| Nearest price level | it is trading 4.4% above a support level at $75.26 — a price it turned at three times since 2026-05-26, most recently on 2026-08-07. Since 2024-08-21 it has 18 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.4% |
| All-time low | its lowest closing price on record is $32.48 (set on 2025-04-09) | $32.48 |
| Above the all-time low | it is 142.4% above its all-time low | +142.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 48th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.63 between its high and its low — about 3.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.63 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $75.44 and $84.82 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $75.44 – $80.13 – $84.82 |
| Typical daily range (% of price) | its price moves about 3.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.3% |
| Stretch from the 200-day average | it is trading 4.0 daily ranges above its 200-day average price (15.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.68× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.7% since the prior reading | -0.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Open gap | it gapped 6.4% below the previous close 12 sessions ago and has not traded back through the level it left behind at 85.33 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -6.4% |
| Gap filled | a 2.5% gap down opened on 2026-06-30 has been "filled" 36 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 36 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.7 percentage points (the stock lost 1.4% while the market gained 2.3%) | -3.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 3.8 percentage points (the stock gained 6.9% while the market gained 3.1%) | +3.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 4.0 percentage points (the stock gained 15.1% while the market gained 11.1%) | +4.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 28.5 percentage points (the stock gained 49.0% while the market gained 20.5%) | +28.5% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 11.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 12% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $70.26 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +12.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $78.97 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -0.3% |
Price levels it has turned at before
LIVN last closed at $78.74 on 2026-08-21. Since 2024-08-21 it has turned at 18 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $75.26 | Support | 4.4% below the last close | turned there three times · 2026-05-26 to 2026-08-07 |
| $85.52 | Resistance | 8.6% above the last close | turned there twice · 2026-07-06 to 2026-08-04 |
| $71.46 | Support | 9.2% below the last close | turned there twice · 2026-02-26 to 2026-06-03 |
| $67.98 | Support | 13.7% below the last close | turned there twice · 2026-02-02 to 2026-04-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $82.70.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $64.76 and $71.61 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $82.70.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · Printed a doji candle · Trading inside the Ichimoku cloud · Elliott wave 3 candidates | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.60 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$88.80 range $75.00 – $100.00; median $91.50
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LIVN
- Consensus EPS estimate$1.06 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant SNIA environmental legal liabilities and associated financial obligations.","Exposure to foreign exchange rate fluctuations affecting operating results.","Dependence on continuous innovation and successful clinical trial outcomes for new product regulatory approvals."]
What changed in the latest 10-Q
AI-assisted comparison of LIVN's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to '2025 Form 10-K' instead of '2024 Form 10-K' (newer filing reflects current year)
- Added 'services' to the mission description: 'products, therapies, and services' (newer filing, May 2026)
- Changed mission statement from 'provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions' to 'create ingenious medical solutions that ignite patient turnarounds' (newer filing, May 2026)
- Removed:
- Removed the detailed mission statement about 'provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions' (older filing, November 2025)
- Removed reference to 'Part II,' at the end of the Macroeconomic section (older filing shows incomplete 'Part II,' whereas newer shows 'Part I,')
- Reworded:
- Reordered impact description from 'consolidated results of operations, financial condition, and/or cash flows' to 'consolidated results of operations, financial condition, and/or cash flows' with 'results of operations, cash flows, and financial condition' in older filing showing different word order
- The older filing ended with '(1) "Part II,' while newer filing ends with 'Part I,' indicating a different cross-reference section
- Notes:
- The comparison involves filings from different quarters (Q1 2026 vs. Q3 2025), which naturally accounts for some dating updates
- The mission statement change represents a substantive rewrite rather than minor wording adjustment
- The incomplete cross-reference at the end of the Macroeconomic section in both texts makes the exact change unclear
Risk Factors
- Added:
- Newer filing references 2025 Form 10-K (filed 2026-05-06) vs older filing references 2024 Form 10-K (filed 2025-11-05)
- Newer filing reports three months ended March 31, 2026 vs older filing reports nine months ended September 30, 2025 and three months ended September 30, 2025
- Newer filing shows net revenue of $362,258 thousand for Q1 2026 vs older filing shows $357,753 thousand for Q3 2025
- Newer filing shows net income of $22,294 thousand vs older filing shows net loss of $(327,322) thousand for comparable periods
- Newer filing shows SNIA environmental liability expense of $0 for Q1 2026 vs older filing shows $(1,745) thousand for Q3 2025
- Newer filing shows cash and cash equivalents of $539,706 thousand as of March 31, 2026 vs older filing shows $646,079 thousand as of September 30, 2025
- Newer filing shows long-term debt obligations of $285,160 thousand vs older filing shows $349,031 thousand
- Newer filing includes 'Impairments of investments' line item of $1,132 thousand in cash flow statement
- Newer filing shows different share repurchase activity with treasury shares reduced from 886,096 to 636,430 ordinary shares
- Removed:
- Older filing included 'Loss on debt extinguishment' line item; not present in newer filing for comparable period
- Older filing included 'Payment of debt extinguishment costs' and 'Purchase of capped calls' in financing activities; not present in newer filing
- Older filing included 'Restricted cash' of $294,698 thousand as of December 31, 2024; not shown in newer filing as of March 31, 2026
- Older filing included nine-month comparative data; newer filing only shows three-month data
- Reworded:
- Older filing references 'Stockholders' Equity' while newer filing uses 'Shareholders' Equity'
- Older filing states 'Please also refer' vs newer filing states 'Also refer' in forward-looking statements section
- Older filing lists 'Shares used in computing' vs newer filing lists 'weighted average shares outstanding'
- Notes:
- The two filings cover different reporting periods (Q1 2026 vs nine-month and Q3 2025 periods), limiting direct comparability of financial results
- Text truncation in older filing cash flow statement prevents full comparison of all financing activities
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($96228) — 1 selling insider
- Last 180 days0 buys · 2 sells ($232578) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-15. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LIVN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
LIVN had 4,143,484 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
LIVN had 7.52% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.91 days to cover at the same settlement.
- Reported short interest (shares) 4,143,484
- Short interest (% of shares outstanding) 7.52%
- Prior settlement (shares) 4,086,510
- Reported change 1.39%
- Days to cover (reported) 7.91
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Edwards Lifesciences (EW)
- Getinge (GETI-B.ST)
- Terumo (4543.T)
- NeuroPace (NPCE)
- Inspire Medical Systems (INSP)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LIVN vs…
Frequently asked questions
What does LIVANOVA PLC (LIVN) do?
LivaNova PLC is a medical technology company focused on cardiovascular and neuromodulation solutions. The company develops and markets devices for cardiac surgery, such as cardiopulmonary bypass systems, as well as neuromodulation therapies for the treatment of drug-resistant epilepsy and obstructive sleep apnea.
What sector is LIVANOVA PLC (LIVN) in?
LIVANOVA PLC (LIVN) is classified in the Health Care sector. Its industry is Medical Devices. It trades on NASDAQ.
Who are LIVANOVA PLC's (LIVN) competitors?
Notable peers of LIVANOVA PLC (LIVN) include Medtronic, Edwards Lifesciences, Getinge (GETI-B.ST), Terumo (4543.T) and NeuroPace. This peer set is informational only — not financial advice.
Is LIVANOVA PLC (LIVN) overbought or oversold right now?
LIVANOVA PLC (LIVN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LIVN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.